Recommended Interval for Intra-Articular Cortisone Injections
Limit cortisone injections to no more than 3-4 injections per year in the same joint, with a minimum interval of approximately 3 months between injections.
Evidence-Based Recommendation
The 2021 EULAR guidelines provide the most authoritative guidance on this topic 1. While acknowledging that high-quality evidence is scarce, the generally accepted rule is to avoid exceeding 3-4 glucocorticoid injections in the same joint per year 1. This translates to a practical minimum interval of 3 months between injections.
Supporting Evidence for 3-Month Intervals
Two randomized controlled trials in knee osteoarthritis specifically tested injections every 3 months for 2 years 1:
- One trial demonstrated symptomatic improvement with no deleterious effects on cartilage volume
- The other showed no pain difference but greater cartilage volume loss with glucocorticoids
This conflicting evidence on cartilage safety reinforces the importance of limiting injection frequency, even though the 3-month interval appears feasible from a practical standpoint.
Clinical Decision-Making Algorithm
Before reinjecting, evaluate:
- Response to previous injections (duration and magnitude of benefit)
- Alternative treatment options available
- Specific glucocorticoid compound previously used
- Current systemic treatments
- Patient comorbidities (especially diabetes)
The decision to reinject should be individualized based on whether the patient experienced meaningful benefit from prior injections 1.
Important Safety Considerations
Pre-Surgical Timing
If the patient is considering joint replacement surgery, maintain at least a 3-month interval between the last injection and surgery 1. Injections within 3 months of total joint arthroplasty showed increased infection rates (0.5% to 1.0% versus background risk of 1.04% to 2.5%), though the absolute increase was modest.
Prosthetic Joints
Avoid routine injections in prosthetic joints 1. The infection rate is approximately 0.6% (1 in 625 injections), and such injections should only be considered by orthopedic surgeons after strict infection screening.
Diabetic Patients
Warn diabetic patients about transient hyperglycemia occurring days 1-3 post-injection and advise glucose monitoring during this period 1.
Key Clinical Pitfalls
- Don't exceed 3-4 injections per year - this limit exists despite lack of robust research evidence, reflecting expert consensus on balancing benefit versus potential cartilage damage
- Don't inject if previous injections provided no benefit - lack of response suggests the patient is unlikely to benefit from repeated injections
- Don't ignore the 3-month pre-surgical window - plan accordingly if arthroplasty is being considered
- Avoid joint overuse for 24 hours post-injection, but don't immobilize the joint as this provides no additional benefit 1
Strength of Evidence Caveat
The EULAR guidelines explicitly acknowledge that "there are no clear evidence-based recommendations as to the appropriate number of IA injections from a risk benefit perspective" 1. The 3-4 injections per year rule represents expert consensus rather than high-quality trial data, making clinical judgment paramount in applying this guideline to individual patients.